Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.
about
Actual long-term outcome of extrahepatic bile duct cancer after surgical resectionManagement of perihilar cholangiocarcinoma in the era of multimodal therapyAdjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection.Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation.Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone.Tumor markers as a diagnostic key for hilar cholangiocarcinoma.Surgical strategy for bile duct cancer: Advances and current limitations.Hilar cholangiocarcinoma: diagnosis, treatment options, and management.Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinomaClinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma.Adenocarcinoma developed from remnant cystic duct after cholecystectomy.Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.Perioperative Management of Hilar Cholangiocarcinoma.Intrahepatic cholangiocarcinoma: expert consensus statement.SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.Management of hilar biliary strictures.Management of combined hepatocellular and cholangiocarcinoma.Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma.Adjuvant surgery for advanced extrahepatic cholangiocarcinoma.Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.Clinical analysis of cholangiocarcinoma patients receiving adjuvant radiotherapy.Does radiotherapy still have a role in unresected biliary tract cancer?Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer.Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer.Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.Molecular factors associated with recurrence and survival following hepatectomy in patients with intrahepatic cholangiocarcinoma: a guide to adjuvant clinical trials.Hepatocellular carcinoma and cholangiocarcinoma: an update.Multimodal treatment strategies for advanced hilar cholangiocarcinoma.Hilar cholangiocarcinoma: expert consensus statement.Klatskin tumor treated by inter-disciplinary therapies including stereotactic radiotherapy: a case report.Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma.Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.A salvage treatment for solid liver metastasis after radical resection of Klatskin tumour.Current management of cholangiocarcinoma.Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.The role of postoperative radiation therapy (PORT) in the treatment of extrahepatic bile duct cancer: a surveillance, epidemiology, and end results (SEER) population-based investigation.Locoregional therapies in cholangiocarcinoma.
P2860
Q24540287-8221AFE1-30EF-4803-BC5C-32102D02F623Q28273788-729412FC-D9F4-401F-8A72-5BD4364E4D0CQ33506777-16E5D6AD-6AEC-4DF3-9288-126F920E3949Q33614103-C226E537-A115-454D-A2CB-3AF73ECF3D37Q34242523-1C85B7C4-8471-4BEB-B67C-1ECDC87DDCABQ34596314-D61D71F1-448C-4450-BCBA-24AF1131AFB6Q34624362-9943F0B1-313F-4F24-B6F9-B8CE44B5F97FQ34629377-16D69EE9-7678-40FB-8A2E-2C6D2FF586C6Q34661001-4941B321-4DF1-4B93-B6AE-3FBF8CA64D2EQ34732888-9B7926D5-1DC1-4F32-A950-585FE920AA78Q34775386-5870FBF6-05DB-4BA6-9B71-14206B33CB73Q34874484-90D26487-12DE-4C86-BE1A-384BF266EA13Q35607681-21EBFE01-81D9-4C47-9BEF-DFBB350A0AB5Q35645739-0F714322-1E39-4927-929E-401FAAAF5D06Q35924971-0760DC2C-BAB3-413E-89FB-F501203CFF8AQ35947011-01F379D6-4FEB-4EDB-A0E2-F8ED93262E30Q37009026-7D55B0C9-EDDA-4A2B-BD8F-98F90438ED30Q37088469-C8443D5D-E6DF-44A1-9476-D57F807D92B2Q37107266-EA7713B3-721E-464F-A126-0DCEEF2BFAA1Q37266457-DFF920C2-77A1-4BC2-9656-DBF71B655B8FQ37347327-7C08747C-6D76-4D92-9D8C-E9238561AC14Q37440707-16A21649-CAED-4319-AB19-1F08ACF799F9Q37582417-A0ADEDC6-BF43-4391-AECF-D9EA2F5E0334Q37609455-C2E5C4B4-4F4F-4CAF-8E73-1138EFDB9ACBQ37687306-81DBE75B-D01B-4CDC-B5D9-C42258960B44Q37692140-F6DF0E2F-D768-4025-AC68-8220F3CC1D28Q37705272-A7CD7E76-DB13-4F6E-8C8A-D79FDE5EF1F5Q37817003-CF256DD5-B61F-4CC8-BD5A-BADFFEA05F31Q38152291-B70A2448-E840-4B7A-A8DC-28B6838343C6Q38163597-B6D391D6-31CC-4916-9DD6-4BE7CF450769Q38222988-2DCC9233-D353-4E99-994B-99FDB261E781Q38546730-AF65A9C2-ABEE-4FD1-A335-CB935D48D0ACQ39677743-386EB4BA-6EB3-411C-AC9B-B3C5A75CE479Q39749219-820E1C16-1296-4850-A81C-D1789B480E68Q40747540-EF74B8C0-1863-4A82-91DE-A70B7CE86184Q42571615-9A7A456A-0F7B-4C07-8E39-AED46AA858D8Q45159737-AF914B65-CA0B-4E57-889C-5CBBDD368E06Q46022234-A0BCCE8A-0688-43F7-9286-0C796BF9BA53Q46155291-03D6F995-5498-4D36-9D1A-A96DDEB6479FQ49474012-874086AE-6412-4B15-BEB3-AF9CBED0D92B
P2860
Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@ast
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@en
type
label
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@ast
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@en
prefLabel
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@ast
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@en
P2093
P1476
Benefits of adjuvant radiother ...... d main hepatic duct carcinoma.
@en
P2093
Kashiwagi H
Kawamoto T
Todoroki T
P304
P356
10.1016/S0360-3016(99)00472-1
P407
P577
2000-02-01T00:00:00Z